What is the honest short answer?
Most comparisons of these two compounds you will encounter set a retatrutide phase 2 number beside a semaglutide phase 3 number and present the difference as a ranking. That is not a valid comparison. The two figures come from trials with different sample sizes, different durations, different eligibility criteria, different sites, and different levels of statistical rigour. Any of those differences alone could shift a result by several percentage points.
How do the two compounds differ mechanistically?
PRECLINICAL PHARMACOLOGY
Semaglutide is a GLP-1 receptor agonist. It binds and activates one receptor, the receptor for glucagon-like peptide-1, a gut hormone released after eating that increases insulin secretion in a glucose-dependent way, slows gastric emptying and affects appetite signalling.
Retatrutide, development code LY3437943, was designed to activate three receptors: GLP-1, GIP and glucagon. The inclusion of the glucagon receptor is the conceptually unusual part, because glucagon is best known for raising blood sugar. The rationale described in the founding pharmacology paper is that glucagon receptor activation also increases energy expenditure, and that combining it with GLP-1 and GIP signalling offsets the glucose-raising effect while retaining the metabolic one. [1]
| Retatrutide | Semaglutide | |
|---|---|---|
| Receptor targets | GLP-1, GIP and glucagon | GLP-1 |
| Highest published evidence level | Phase 2 randomised trials | Phase 3 and cardiovascular outcomes trials |
| Regulatory status | Investigational, not approved | Approved for type 2 diabetes and chronic weight management |
| Published obesity trial size | 338 participants, 48 weeks | 1,961 participants, 68 weeks (STEP 1) |
| Cardiovascular outcomes | TRIUMPH-Outcomes registered, no results | SELECT, 17,604 participants, MACE 6.5% vs 8.0%, HR 0.80 |
The three-receptor design is explained in more depth in How does retatrutide work?.
What did each compound's trials actually measure?
HUMAN — SEPARATE TRIALS, NOT A HEAD-TO-HEAD COMPARISON
The retatrutide phase 2 obesity trial randomised 338 adults across four dose groups and placebo. At 48 weeks, average weight change was −8.7%, −17.1%, −22.8% and −24.2% across the dose groups, against −2.1% on placebo. The pre-specified primary endpoint was at 24 weeks; the 48-week figures are secondary. [2]
The semaglutide STEP 1 trial randomised 1,961 adults with overweight or obesity and reported an average weight change of −14.9% against −2.4% on placebo over 68 weeks. [3]
Setting −24.2% beside −14.9% looks decisive and is not. The retatrutide figure comes from a phase 2 trial roughly one-sixth the size, run for 20 fewer weeks, with a different placebo response of −2.1% against −2.4%. Phase 2 results also tend to be produced in smaller, more tightly selected populations than phase 3 results, and effect sizes commonly change when a compound moves from one to the other. The correct reading is that retatrutide's phase 2 signal was large enough to justify a phase 3 programme, and that what phase 3 shows is not yet published.
Comparing a phase 2 result with a phase 3 result across separate trials is not a like-for-like comparison and should not be presented as one.
Will there ever be a direct comparison?
HUMAN — REGISTERED TRIAL, NO RESULTS
One registered trial compares the two compounds directly. TRANSCEND-T2D-2, ClinicalTrials.gov identifier NCT06260722, is a randomised open-label trial of retatrutide against semaglutide in type 2 diabetes. It was recorded as active and not recruiting, with no posted results, when the registry was checked on September 18, 2026. [6]
Note the population: type 2 diabetes, not obesity. Even when it reports, it will answer the comparison question for people with diabetes, which is a different question from how the two compounds compare in people with obesity and without diabetes. No registered head-to-head trial in an obesity population was identifiable.
Separately, TRIUMPH-5 is registered with tirzepatide, not semaglutide, as its active comparator, so it will not answer this particular question either. [7]
What should qualify any comparison?
- Retatrutide's published evidence is phase 2 only. Phase 3 results exist as completed trials but have not been peer-reviewed or posted.
- Semaglutide has published phase 3 efficacy data and a placebo-controlled cardiovascular outcomes trial; retatrutide has neither published.
- No head-to-head obesity trial exists, so any efficacy ranking between the two is inference, not evidence.
- Adverse event profiles cannot be compared across separate trials with different populations and reporting conventions.
- Retatrutide is not approved. Nothing here describes a dosing protocol or a therapeutic use.
For the other three-receptor comparison, see Tirzepatide vs retatrutide.
For all three compounds side by side, see retatrutide vs tirzepatide vs semaglutide.
Frequently Asked Questions
Is retatrutide more effective than semaglutide?
There is no head-to-head trial in an obesity population, so this cannot be answered from evidence. Retatrutide's phase 2 trial reported larger percentage weight changes than semaglutide's phase 3 STEP 1 trial, but the two trials differed in size, duration, population and phase, which makes the comparison unreliable.
How many receptors does each compound target?
Retatrutide was designed to activate three receptors: GLP-1, GIP and glucagon. Semaglutide activates one, GLP-1.
Is there a trial comparing them directly?
TRANSCEND-T2D-2 (NCT06260722) is a registered randomised open-label trial comparing retatrutide with semaglutide in type 2 diabetes. It was active and not recruiting with no posted results when checked on September 18, 2026. No head-to-head trial in obesity was identifiable.
Does retatrutide have cardiovascular outcome data?
No published data. TRIUMPH-Outcomes is a registered cardiovascular outcomes trial with an estimated enrolment of 10,000 and no posted results. Semaglutide has published cardiovascular outcome data from the SELECT trial.
